Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT04491370 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

B-cell Lymphoma
Burkitt Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Transformed Non-Hodgkin Lymphoma
Richter Syndrome
Hodgkin Lymphoma

Interventions

DRUG: Polatuzumab vedotin

Sponsor

New York Medical College